Pharvaris (NASDAQ:PHVS) Short Interest Update

Pharvaris (NASDAQ:PHVS) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 390,900 shares, a growth of 25.7% from the January 31st total of 311,100 shares. Approximately 2.3% of the shares of the company are sold short. Based on an average daily volume of 64,900 shares, the short-interest ratio is currently 6.0 days.

Pharvaris Trading Down 0.1 %

NASDAQ PHVS traded down $0.02 on Thursday, reaching $14.98. 47,964 shares of the stock were exchanged, compared to its average volume of 71,497. Pharvaris has a one year low of $14.37 and a one year high of $27.46. The firm has a market capitalization of $783.04 million, a PE ratio of -5.35 and a beta of -3.02. The company’s 50-day simple moving average is $17.57 and its two-hundred day simple moving average is $19.24.

Wall Street Analyst Weigh In

Separately, JMP Securities upped their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio purchased a new stake in Pharvaris in the 3rd quarter worth $57,000. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after purchasing an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Pharvaris during the 4th quarter valued at approximately $64,000. Barclays PLC purchased a new position in Pharvaris in the 3rd quarter worth approximately $106,000. Finally, KLP Kapitalforvaltning AS bought a new position in Pharvaris in the 4th quarter worth approximately $111,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.